ZDHHC1

Across TCGA pan-cancer cohorts, ZDHHC1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZDHHC1 data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZDHHC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and STAD are the cancer types where ZDHHC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.132	0.684	<.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.483	.021	18	view →
STAD	OS	Median	III,IV	0.003	0.630	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZDHHC1–BLCA (OS)

Open the BLCA breakdown →